Advertisement

Annals of Hematology

, Volume 91, Issue 9, pp 1393–1401 | Cite as

Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma

  • Ji-Sun Paik
  • Won-Kyung Cho
  • Sung-Eun Lee
  • Byung-Ock Choi
  • Seung-Eun Jung
  • Gyeong-Sin Park
  • Sung-Hoon Kim
  • Suk-Woo YangEmail author
  • Seok-Goo ChoEmail author
Original Article

Abstract

In the present study, we evaluated the ophthalmologic outcomes of 24 patients who received chemotherapy and/or radiotherapy for the treatment of non-conjunctival ocular adnexal mucosa-associated lymphoid tissue-type (MALT) lymphoma. Ophthalmologic outcomes were assessed in patients who received chemotherapy and/or radiotherapy from March 2004 until May 2010. Outcomes were determined according to common symptoms following chemotherapy and/or radiotherapy, which consisted of decreased visual acuity, dry eye symptoms, retinopathy, optic neuropathy, increased intraocular pressure, and blepharitis. Nine patients received chemotherapy alone, eight patients received radiotherapy alone, and seven patients received chemotherapy with additional radiotherapy (chemoradiation therapy). Patients treated by chemotherapy alone showed better ophthalmologic outcome scores (mean score, 1.56) than those treated by radiation alone or chemoradiation therapy (mean score, 4.01). In conclusion, the treatment of ocular adnexal lymphoma including radiotherapy showed poor ophthalmologic outcomes due to radiation-induced complications. Recently, many new treatment options have emerged, such as immunotherapy or radioimmunotherapy. In the future study, to select a better treatment modality with fewer complications, well-designed prospective trials with ophthalmologic outcomes are needed.

Keywords

Non-conjunctival MALT lymphoma Ophthalmologic outcomes Radiotherapy Chemotherapy 

Notes

Funding/support

The authors did not receive any funding or financial support.

Disclosures

The authors do not have anything to disclose. The authors do not have financial interest for the treatment of ocular adnexal lymphoma.

This paper was not presented in any other international meetings.

Competing interests

None to declare. No conflicting relationship exists for any authors.

References

  1. 1.
    Bairey O, Kremer I, Rakowsky E, Hadar H, Shaklai M (1994) Orbital and adnexal involvement in systemic non-Hodgkin’s lymphoma. Cancer 73:2395–2399PubMedCrossRefGoogle Scholar
  2. 2.
    Freeman C, Berg J, Cutler S (1972) Occurrence and prognosis of extranodal lymphomas. Cancer 29:252–260PubMedCrossRefGoogle Scholar
  3. 3.
    White WL, Ferry JA, Harris NL, Grove AS Jr (1995) Ocular adnexal lymphoma: a clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue (MALT) type. Ophthalmology 102:1994–2006PubMedGoogle Scholar
  4. 4.
    Ohtsuka K, Hashimoto M, Suzuki Y (2005) A review of 244 orbital tumors in Japanese patients during a 21-year period: origins and locations. Jpn J Ophthalmol 49:49–55PubMedCrossRefGoogle Scholar
  5. 5.
    Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, Harris NL, Ferry JA (2003) Ocular adnexal lymphoma: clinical behavior or distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 57:1382–1391PubMedCrossRefGoogle Scholar
  6. 6.
    Cho EY, Han JJ, Ree HJ, Ko YH, Kang YK, Ahn HS, Park CJ, Huh J (2003) Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Korean and affects younger patients. Am J Hematol 73:87–96PubMedCrossRefGoogle Scholar
  7. 7.
    Hasegawa M, Kojima M, Shioya M, Tamaki Y, Saitoh J, Sakurai H, Kitamoto Y, Suzuki Y, Niibe H, Nakano T (2003) Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys 57:172–176PubMedCrossRefGoogle Scholar
  8. 8.
    Uno T, Isobe K, Shikama N, Nishikawa A, Oguchi M, Ueno N, Itami J, Ohnishi H, Mikata A, Ito H (2003) Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer 98:865–871PubMedCrossRefGoogle Scholar
  9. 9.
    Cahill M, Barnes C, Moriarty P, Daly P, Kennedy S (1999) Ocular adnexal lymphoma—comparison of MALT lymphoma with other histologic types. Br J Ophthalmol 83:742–747PubMedCrossRefGoogle Scholar
  10. 10.
    Lee JL, Kim MK, Lee KH, Hyun MS, Chung HS, Kim DS, Shin SO, Cho HS, Bae SH, Ryoo HM (2005) Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 84:13–18PubMedCrossRefGoogle Scholar
  11. 11.
    Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ (2003) Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21:4157–4164PubMedCrossRefGoogle Scholar
  12. 12.
    Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA (2006) Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 113:1209–1213PubMedCrossRefGoogle Scholar
  13. 13.
    Song EK, Kim SY, Kim TM, Lee KW, Yun T, Na II, Shin H, Lee SH, Kim DW, Khwarg SI, Heo DS (2008) Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol 19:242–246PubMedCrossRefGoogle Scholar
  14. 14.
    Kashiwagi H (2010) Ocular disorders of anticancer drugs—ocular side effects. Gan To Kagaku Ryoho 37:1639–1644PubMedGoogle Scholar
  15. 15.
    al-Tweigeri T, Nabholtz JM, Mackey JR (1996) Ocular toxicity and cancer therapy. A review. Cancer 78:1359–1373PubMedCrossRefGoogle Scholar
  16. 16.
    Mannami T, Yoshino T, Oshima K, Takase S, Kondo E, Ohara N, Nakagawa H, Ohtsuki H, Harada M, Akagi T (2001) Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of MALT lymphoma and reactive lymphoid hyperplasia. Mod Pathol 14:641–649PubMedCrossRefGoogle Scholar
  17. 17.
    Yoon JS, Ma KT, Kim SJ, Kook K, Lee SY (2007) Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions. Ophthal Plast Reconstr Surg 23:94–99PubMedCrossRefGoogle Scholar
  18. 18.
    Wenzel C, Fiebiger W, Dieckmann K, Formanek M, Chott A (2003) Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy. Cancer 97:2236–2241PubMedCrossRefGoogle Scholar
  19. 19.
    Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, Demeter J, Zallio F, Palmas A, Muti G, Dognini GP, Pasini E, Lettini AA, Sacchetti F, De Conciliis C, Doglioni C, Dolcetti R (2006) Bacteria-eradicating therapy with doxycyclin in ocular adnexal MATL lymphoma: a multicenter prospective trial. J Natl Cancer Inst 98:1375–1382PubMedCrossRefGoogle Scholar
  20. 20.
    Stefanovic A, Lossos IS (2009) Extranodal marginal zone lymphoma of the ocular adnexa. Blood 114:501–510PubMedCrossRefGoogle Scholar
  21. 21.
    McKelvie PA (2010) Ocular adenexal lymphoma: a review. Adv Anat Pathol 17:251–261PubMedCrossRefGoogle Scholar
  22. 22.
    Ejima Y, Sasaki R, Okamoto Y, Maruta T, Azumi A, Hayashi Y, Demizu Y, Ota Y, Soejima T, Sugimura K (2006) Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol 78:6–9PubMedCrossRefGoogle Scholar
  23. 23.
    Suh CO, Shim SJ, Lee SW, Yang WI, Lee SY, Hahn JS (2006) Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys 65:228–233PubMedCrossRefGoogle Scholar
  24. 24.
    Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, Dua HS, Hom M, Karpecki PM, Laibson PR, Lemp MA, Meisler DM, Del Castillo JM, O'Brien TP, Pflugfelder SC, Rolando M, Schein OD, Seitz B, Tseng SC, van Setten G, Wilson SE, Yiu SC, Dysfunctional tear syndrome study group (2006) Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 25:900–907PubMedCrossRefGoogle Scholar
  25. 25.
    Coupland SE, White VA, Rootman J, Damato B, Finger PT (2009) A TNM-based clinical staging system of ocular adnexal lymphomas. Arch Pathol Lab Med 133:1262–1267PubMedGoogle Scholar
  26. 26.
    Lee SE, Paik JS, Cho WK, Choi BO, Lee SN, Jung SE, Park KS, Kang CS, Kim SH, Yang SW, Cho SG (2011) Feasibility of the TNM-based system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Am J Hematol 86:262–266PubMedCrossRefGoogle Scholar
  27. 27.
    McKelvie PA, McNab A, Francis IC, Fox R, O’Day J (2001) Ocular adnexal lymphoproliferative disease: a series of 73 cases. Clin Exp Ophthalmol 29:387–393CrossRefGoogle Scholar
  28. 28.
    Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Anagnostopoulos I, Stein H (2005) Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases. Br J Ophthalmol 89:352–359PubMedCrossRefGoogle Scholar
  29. 29.
    Kao SC, Kau HC, Tsai CC, Tsay SH, Yang CF, Wu JS, Hsu WM (2007) Lacrimal gland extranodal marginal zone B-cell lymphoma of MALT-type. Am J Ophthalmol 143:311–316PubMedCrossRefGoogle Scholar
  30. 30.
    Nam H, Ahn YC, Kim YD, Ko Y, Kim WS (2009) Prognostic significance of anatomic subsites: results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma. Radiother Oncol 90:236–241PubMedCrossRefGoogle Scholar
  31. 31.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586PubMedCrossRefGoogle Scholar
  32. 32.
    Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Kagami Y, Maeshima A, Matsuno Y, Tobinai K (2006) Long term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol 17:135–140PubMedCrossRefGoogle Scholar
  33. 33.
    Shome D, Esmaeli B (2008) Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of ocular adnexa. Curr Opin Ophthalmol 19:414–421PubMedCrossRefGoogle Scholar
  34. 34.
    Rigacci L, Nassi L, Puccioni M, Mappa S, Polito E, Dal Pozzo S, Alterini R, Carrai V, Puccini B, Bosi A (2007) Rituximab and chlorambucil as first-line treatment for low grade ocular adnexal lymphomas. Ann Hematol 86:565–868PubMedCrossRefGoogle Scholar
  35. 35.
    Zucca E, Conconi A, Martinelli G et al. (2010) Chlorambucil plus rituximab produces better event-free survival in comparison with chlorambucil alone in the treatment of MALT lymphoma: 5-year analysis of the 2-arms part of the IELSG-19 randomized study. Blood. ASH Annual Meeting Abstracts 116:Abstract 432Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Ji-Sun Paik
    • 1
    • 7
  • Won-Kyung Cho
    • 1
    • 7
  • Sung-Eun Lee
    • 2
    • 7
  • Byung-Ock Choi
    • 3
    • 7
  • Seung-Eun Jung
    • 4
    • 7
  • Gyeong-Sin Park
    • 5
    • 7
  • Sung-Hoon Kim
    • 6
    • 7
  • Suk-Woo Yang
    • 1
    • 7
    Email author
  • Seok-Goo Cho
    • 2
    • 7
    Email author
  1. 1.Department of Ophthalmology and Visual Science, College of Medicine, Seoul St. Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea
  2. 2.Department of Hematology, Catholic BMT Center, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  3. 3.Department of Radiation Oncology, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  4. 4.Department of Radiology, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  5. 5.Department of Pathology, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  6. 6.Department of Nuclear Medicine, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaSeoulSouth Korea
  7. 7.Catholic University Lymphoma GroupThe Catholic University of KoreaSeoulSouth Korea

Personalised recommendations